Osteoarthritis of knee. Osteoarthritis of knee
Conditions
Interventions
Intervention 1: Intervention group: Patients with primary osteoarthritis receive a 30 mg soft capsule of b-caryophyllene made by Mashhad University of Medical Sciences. Patients take this soft capsule
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Lack of proper response (having a score higher than 30 on the VAS numerical-visual scale at the beginning of the study) to the analgesic drug meloxicam after at least two weeks of drug administration before the start of the study Age between 40-70 years old Patients with BMI lower than 37
Exclusion criteria
Exclusion criteria: Patient's dissatisfaction with continued cooperation during the study Need to perform any new therapeutic interventions during the study period Active liver or kidney disease and malignancies Secondary or suspected osteoarthritis Patients treated with hormonal medicines Patients treated with anticoagulants Patients with a history of ischemic or hemorrhagic stroke Patients with a history of deep vein thrombosis Treatment with oral corticosteroids 4 weeks before the start of the study Intra-articular injection of hyaluronic acid three months before the start of the study Pregnancy Patients who have had intra-articular corticosteroid injections in the last 4 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical indicators of osteoarthritis. Timepoint: At the beginning of the study and every week until the eighth week. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) standardized questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Blood Cell Count with Differential. Timepoint: At the beginning and the end of the study. Method of measurement: Using an auto-analyzer system.;Interleukin-4 level. Timepoint: At the end of the study. Method of measurement: Using a laboratory kit.;Interferon-gamma level. Timepoint: At the end of the study. Method of measurement: Using a laboratory kit.;Interleukin-10 level. Timepoint: At the end of the study. Method of measurement: Using a laboratory kit.;High-sensitivity C-reactive protein (hs-CRP) level. Timepoint: At the beginning and the end of the study. Method of measurement: Using a laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Reza Askari
Mashhad University of Medical Sciences
Outcome results
None listed